contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-plc-1837571-new-shares-registered-with-the-trade-register

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Eli Lilly buying cell therapy pharma know how BARRONS  Feb 9 2026

Here are Antti’s comments on how Herantis successfully executed a directed share issue  Herantis announced late on Wednesday that it has successfully completed a EUR 4.2 million directed share issue. The funding will be used to prepare for the Phase II study of the HER-096 drug candidate and, according to the company, it supports ongoing partnership negotiations. The bridge financing provides the company with room to maneuver at a time when biotechnology stocks have been under pressure in the market. We will update the information regarding the issue in our forecasts by the time of the financial statement report at the latest.                   Inderes              Herantis vahvisti rahoitusasemaa suunnatulla annilla - Inderes    Suunnattu 4,2 MEUR:n osakeanti varmistaa yhtiön asemaa heiluvilla markkinoilla.

Very relieving news regarding the share issue. Investors have clear confidence in Herantis, in contrast to the ongoing “share issue crisis” at Faron. With the offering, Herantis can steadily continue its work for the benefit of Parkinson’s patients.

Financing, i.e. a directed issue. €4.2M, €1.75/share.                   Tärkeimmät talousuutiset | Kauppalehti – 11 Feb 26              Sisäpiiritieto: Herantis Pharma Oyj toteuttaa onnistuneesti suunnatun...    Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdestä.

14th Alzheimer's & Parkinson's Drug Development Summit              Full Event Guide    Discover the Full Event Guide to plan your participation in expert talks and interactive sessions on neuro-degenerative care and research.                             HER-096 has been in good company; I wonder how full the room was for Kira’s presentation on Thursday?  Out of Antti’s 6-9 month partnering window, 4 months are now starting to be filled. Since the company’s current funding lasts until Q2, the time windows align quite nicely.

Thank you for sharing this. Very good information, even though most of it was already familiar. But it’s good to know where things stand right now.

Discovery made at the University of Helsinki in the early 2000s – now drug developer aims to stop Parkinson’s disease with it | Uusimaa | Yle

Herantis Pharma

Herantis Pharma Plc Company release, 13 February 2026 at 11:50 EETHerantis Pharma Plc: 1,837,571 new shares registered with the trade registerTHE INFORMATION CONTAINED IN THIS RELEASE IS NOT...

Herantis Pharma Plc Company release, 13 February 2026 at 11:50 EETHerantis Pharma Plc: 1,837,571 new shares registered with the trade registerTHE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.Herantis Pharma Plc ("Herantis" or the "Company"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announced on 11 February 2026 the result of the offering of new shares in a directed share issue to institutional and other qualified investors (the "Directed Issue"). In the Directed Issue, the Company issued a total of 2,409,000 new shares, of which 1,837,571 new shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office (the "New Shares").Following the registration of the New Shares, the total number of registered shares in the Company is 25,932,388. The New Shares will be issued in the book-entry system (ISIN code FI4000087861) and will be registered on the investors' book-entry accounts after which the New Shares will confer shareholder rights in the Company. The New Shares are expected to be ready for delivery to the investors through Euroclear Finland Ltd on or about 16 February 2026.Trading in the New Shares is expected to commence on Nasdaq First North Growth Market Finland on or about 16 February 2026.The remaining 571,429 new shares are expected to be registered, delivered to investors and listed later in February 2026.Herantis Pharma Plc The Board of DirectorsFor more information, please contact:Tone Kvåle, CFOTel: +47 915 19576Email:&nbsp;<a href="mailto:ir@herantis.com">ir@herantis.com</a>Certified Advisor:UB Corporate Finance LtdTel.: +358 9 25 380 225E-mail:&nbsp;<a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>About Herantis Pharma PlcHerantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients.Herantis is listed on the Nasdaq First North Growth Market Finland.Company website: <a href="http://www.herantis.com">www.herantis.com</a>